查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1587544

大腸激躁症治療市場規模、佔有率、分析報告：2025-2030 年按類型、產品、分銷管道、地區和細分市場預測

Irritable Bowel Syndrome Treatment Market Size, Share & Analysis Report By Type (IBS-C, IBS-D), By Product (Xifaxan, Linzess/Constella, Viberzi, Amitiza), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

大腸激躁症治療市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，2030年全球大腸激躁症治療市場規模預計將達到60.2億美元，2025年至2030年複合年成長率為8.8%。

目標疾病盛行率的上升和現有藥物適應症的擴大可能會加速市場成長。此外，藥物的滲透和新產品的推出預計將推動大腸激躁症（IBS）治療市場的發展。

IBS 是最常見的胃腸道疾病之一，全球盛行率通常在 10% 至 15% 之間。儘管大多數腸躁症患者年齡在 50 歲以下，但許多老年人也受到影響。症狀的影響範圍從輕微的不便到嚴重的虛弱。 IBS 可以影響患者工作、情緒和社交生活的許多方面。患有中度至重度疾病的患者通常會與經常損害他們的情感、身體、教育、社交和財務健康的症狀作鬥爭。

症狀多種多樣，有時甚至是矛盾的，便秘和腹瀉交替出現。長期症狀會干擾患者的工作和個人活動，通常會限制個人的潛力。這些因素進一步增加了治療大腸激躁症的需要，以便患者能夠過正常的生活。

約40%的患者患有輕度IBS，35%患有中度IBS，25%患有重度IBS。許多人無法辨識腸躁症的症狀，它仍然是醫生診斷的最常見疾病之一。並非所有有腸躁症症狀的人都會接受治療。然而，光是在美國，每年就有 240 至 350 萬人次因大腸激躁症就診。在全球範圍內，它影響了大約 35-40% 的男性和 60-65% 的女性。

大腸激躁症治療市場報告亮點

  • 由於 Linzes（Linaclotide）和 Amitiza（魯比前列酮）等有效藥物的普及和採用的增加，預計 IBS-C 領域在預測期內將以 11.9% 的複合年成長率成長。
  • 由於診斷病例的增加以及對生活品質影響的更好理解，IBS-D 領域在 2024 年以 49.8% 的最大銷售佔有率佔據市場主導地位。
  • Lindseth/Constella 佔據市場主導地位，2024 年佔據最大銷售佔有率，達到 37.3%。
  • 醫院藥局引領市場，並在 2024 年佔據最大的收益佔有率。這是由於其全面的基礎設施和綜合患者照護系統。
  • 北美大腸激躁症（IBS）治療市場主導全球市場，2024年佔最大收益佔有率為37.5%。
  • 歐洲大腸激躁症治療市場的成長是由旨在減少胃腸道疾病恥辱感的宣傳活動不斷加強所推動的。在德國和英國等國家，患者對 IBS 症狀和可用治療方法的參與度正在增加。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章大腸激躁症治療市場變數、趨勢、範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 大腸激躁症治療市場分析工具
    • 波特的分析
    • PESTEL分析

第4章大腸激躁症治療市場：類型估計和趨勢分析

  • 2024 年和 2030 年按類型分類的市場佔有率
  • 類型細分儀表板
  • 2018-2030 年按類型分類的市場規模、預測與趨勢分析
  • IBS-C
  • IBS-D

第5章大腸激躁症治療市場：藥物類別估計與趨勢分析

  • 2024 年及 2030 年藥品類別市場佔有率
  • 藥品類別細分儀表板
  • 2018-2030 年按藥物類別分類的市場規模、預測與趨勢分析
  • 西法克生
  • 林塞斯/康斯特拉
  • 維貝爾吉
  • 阿米蒂扎
  • 其他

第6章大腸激躁症治療市場：通路估計與趨勢分析

  • 2024 年及 2030 年分銷通路市場佔有率
  • 分銷通路細分儀表板
  • 2018-2030 年按分銷管道分類的市場規模、預測與趨勢分析
  • 醫院藥房
  • 零售藥房
  • 其他

第7章大腸激躁症治療市場：區域估計與趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
  • 亞太地區
    • 中國
    • 日本
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非

第8章 競爭格局

  • 參與者概覽
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介
    • Ironwood Pharmaceuticals, Inc.
    • Allergan
    • Astellas Pharma, Inc.
    • Takeda Pharmaceutical Company Limited
    • AstraZeneca
    • Sanofi SA
    • Sebela Pharmaceuticals Inc
    • Bausch Health
    • Synthetic Biologics, Inc
    • Ardelyx
Product Code: GVR-3-68038-319-5

Irritable Bowel Syndrome Treatment Market Growth & Trends:

The global irritable bowel syndrome treatment market size is expected to reach USD 6.02 billion by 2030, registering a CAGR of 8.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rising prevalence of target disease and increasing label extension of existing drugs are likely to accelerate market growth. In addition, growing uptake of drugs and launch of novel products are anticipated to drive the irritable bowel syndrome (IBS) treatment market.

IBS is one of the most common gastrointestinal disorders, with the worldwide prevalence rate usually ranging between 10-15%. Most of the patients with IBS are under 50 years of age but many older adults suffer as well. The effect of the condition can vary from mild inconvenience to serious debilitation. It can control many facets of a patient's professional, emotional, and social life. Patients with moderate to severe conditions usually struggle with symptoms that frequently impair their emotional, physical, educational, social, and economic wellbeing.

Symptoms can vary and are sometimes contradictory, constipation can alternate with diarrhea. Long-term symptoms can disturb the patient's professional and personal activities, and usually limits an individual's potential.These factors further increase the need for irritable bowel syndrome treatment, which enable patients to go on with their regular life.

Around 40% patients have mild IBS, 35% have moderate IBS, and 25% have severe IBS. A significant number of people cannot distinguish IBS symptoms; it is still one of the most common disorders diagnosed by physicians. Not everyone with IBS symptoms pursues treatment for the same. Though, there are around 2.4-3.5 million yearly doctor visits for irritable bowel syndrome in U.S. alone. Globally, it affects around 35-40% of males and 60-65% of females.

Irritable Bowel Syndrome Treatment Market Report Highlights:

  • The IBS-C segment is expected to grow at a CAGR of 11.9% over the forecast period, owing to the increasing prevalence of this condition and the rising adoption of effective medications such as Linzess (linaclotide) and Amitiza (lubiprostone).
  • The IBS-D segment dominated the market with the largest revenue share of 49.8% in 2024 attributed to a rise in diagnosed cases and an increasing understanding of the condition's impact on quality of life.
  • Linzess/Constella dominated the market and accounted for the largest revenue share of 37.3% in 2024 attributed to its effectiveness in managing constipation-predominant IBS (IBS-C).
  • Hospital pharmacies led the market and accounted for the largest revenue share in 2024, which is attributed to their comprehensive infrastructure and integrated patient care systems.
  • North America irritable bowel syndrome (IBS) treatment market dominated the global market and accounted for the largest revenue share of 37.5% in 2024 attributed to the high prevalence of IBS and the increasing awareness of its management options.
  • The growth of Europe irritable bowel syndrome treatment market is driven by increasing awareness campaigns aimed at destigmatizing gastrointestinal disorders. Countries such as Germany and the UK are seeing increased patient engagement regarding IBS symptoms and available treatments.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Irritable Bowel Syndrome Treatment Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Irritable Bowel Syndrome Treatment Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Irritable Bowel Syndrome Treatment Market: Type Estimates & Trend Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. IBS-C
    • 4.4.1. IBS-C Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. IBS-D
    • 4.5.1. IBS-D Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Irritable Bowel Syndrome Treatment Market: Drug Class Estimates & Trend Analysis

  • 5.1. Drug Class Market Share, 2024 & 2030
  • 5.2. Drug Class Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 5.4. Xifaxan
    • 5.4.1. Xifaxan Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Linzess/Constella
    • 5.5.1. Linzess/Constella Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Viberzi
    • 5.6.1. Viberzi Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Amitiza
    • 5.7.1. Amitiza Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Irritable Bowel Syndrome Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2030
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel , 2018 to 2030 (USD Million)
  • 6.4. Hospital Pharmacy
    • 6.4.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Retail Pharmacy
    • 6.5.1. Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Irritable Bowel Syndrome Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. China
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. China Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Japan
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. Japan Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Ironwood Pharmaceuticals, Inc.
      • 8.5.1.1. Participant's Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Recent Developments/ Strategic Initiatives
    • 8.5.2. Allergan
      • 8.5.2.1. Participant's Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Recent Developments/ Strategic Initiatives
    • 8.5.3. Astellas Pharma, Inc.
      • 8.5.3.1. Participant's Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Recent Developments/ Strategic Initiatives
    • 8.5.4. Takeda Pharmaceutical Company Limited
      • 8.5.4.1. Participant's Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Recent Developments/ Strategic Initiatives
    • 8.5.5. AstraZeneca
      • 8.5.5.1. Participant's Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Recent Developments/ Strategic Initiatives
    • 8.5.6. Sanofi S.A
      • 8.5.6.1. Participant's Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Recent Developments/ Strategic Initiatives
    • 8.5.7. Sebela Pharmaceuticals Inc
      • 8.5.7.1. Participant's Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Recent Developments/ Strategic Initiatives
    • 8.5.8. Bausch Health
      • 8.5.8.1. Participant's Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Recent Developments/ Strategic Initiatives
    • 8.5.9. Synthetic Biologics, Inc
      • 8.5.9.1. Participant's Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Recent Developments/ Strategic Initiatives
    • 8.5.10. Ardelyx
      • 8.5.10.1. Participant's Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Recent Developments/ Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Irritable Bowel Syndrome Treatment Market, by Region, 2018 - 2030 (USD Million)
  • Table 4 Global Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 5 Global Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 6 Global Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 7 North America Irritable Bowel Syndrome Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 8 North America Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 9 North America Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 10 North America Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 U.S. Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 12 U.S. Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 13 U.S. Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 14 Canada Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 15 Canada Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 16 Canada Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 17 Europe Irritable Bowel Syndrome Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 18 Europe Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 19 Europe Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 20 Europe Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 21 UK Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 22 UK Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 23 UK Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 24 Germany Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 25 Germany Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 26 Germany Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 27 France Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 28 France Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 29 France Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 30 Italy Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 31 Italy Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 32 Italy Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 33 Spain Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 34 Spain Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 35 Spain Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific Irritable Bowel Syndrome Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 37 Asia Pacific Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 38 Asia Pacific Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 39 Asia Pacific Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 40 Japan Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 41 Japan Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 42 Japan Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 43 China Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 44 China Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 45 China Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 46 Latin America Irritable Bowel Syndrome Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 47 Latin America Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 48 Latin America Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 49 Latin America Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 50 Brazil Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 51 Brazil Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 52 Brazil Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 53 Argentina Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 54 Argentina Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 55 Argentina Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Irritable Bowel Syndrome Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 59 Middle East & Africa Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 60 South Africa Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 61 South Africa Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 62 South Africa Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Irritable Bowel Syndrome Treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Segment outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Irritable bowel syndrome treatment market dynamics
  • Fig. 12 Irritable bowel syndrome treatment market: Porter's five forces analysis
  • Fig. 13 Irritable bowel syndrome treatment market: PESTLE analysis
  • Fig. 14 Irritable bowel syndrome treatment market: Type segment dashboard
  • Fig. 15 Irritable bowel syndrome treatment market: Type market share analysis, 2024 & 2030
  • Fig. 16 IBS-C market, 2018 - 2030 (USD Million)
  • Fig. 17 IBS-D market, 2018 - 2030 (USD Million)
  • Fig. 18 Irritable bowel syndrome treatment market: Drug class segment dashboard
  • Fig. 19 Irritable bowel syndrome treatment market: Drug class market share analysis, 2024 & 2030
  • Fig. 20 Xifaxan market, 2018 - 2030 (USD Million)
  • Fig. 21 Linzess/Constella market, 2018 - 2030 (USD Million)
  • Fig. 22 Viberzi market, 2018 - 2030 (USD Million)
  • Fig. 23 Amitiza market, 2018 - 2030 (USD Million)
  • Fig. 24 Others market, 2018 - 2030 (USD Million)
  • Fig. 25 Irritable bowel syndrome treatment market: Distribution Channel segment dashboard
  • Fig. 26 Irritable bowel syndrome treatment market: Distribution channel market share analysis, 2024 & 2030
  • Fig. 27 Hospital pharmacy market, 2018 - 2030 (USD Million)
  • Fig. 28 Retail pharmacy market, 2018 - 2030 (USD Million)
  • Fig. 29 Others market, 2018 - 2030 (USD Million)
  • Fig. 30 Irritable bowel syndrome treatment market revenue, by region
  • Fig. 31 Regional marketplace: Key takeaways
  • Fig. 32 North America irritable bowel syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. country dynamics
  • Fig. 34 U.S. irritable bowel syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 35 Canada country dynamics
  • Fig. 36 Canada irritable bowel syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 37 Europe irritable bowel syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 38 UK country dynamics
  • Fig. 39 UK irritable bowel syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 40 Germany country dynamics
  • Fig. 41 Germany irritable bowel syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 42 France country dynamics
  • Fig. 43 France irritable bowel syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 44 Italy country dynamics
  • Fig. 45 Italy irritable bowel syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 46 Spain country dynamics
  • Fig. 47 Spain irritable bowel syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 48 Asia Pacific irritable bowel syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 49 Japan country dynamics
  • Fig. 50 Japan irritable bowel syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 51 China country dynamics
  • Fig. 52 China irritable bowel syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 53 Latin America irritable bowel syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 54 Brazil country dynamics
  • Fig. 55 Brazil irritable bowel syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 56 Argentina country dynamics
  • Fig. 57 Argentina irritable bowel syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 58 MEA irritable bowel syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 60 South Africa country dynamics
  • Fig. 61 South Africa irritable bowel syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 62 Company categorization
  • Fig. 63 Company market position analysis
  • Fig. 64 Strategic framework